<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01873690</url>
  </required_header>
  <id_info>
    <org_study_id>103696</org_study_id>
    <nct_id>NCT01873690</nct_id>
  </id_info>
  <brief_title>Efficacy of Antimicrobial Prophylaxis for Shock Wave Lithotripsy (SWL) on Reducing Urinary Tract Infection (UTI)</brief_title>
  <official_title>A Randomized Controlled Trial Assessing the Efficacy of Antimicrobial Prophylaxis for Extracorporeal Shock Wave Lithotripsy on Reducing Urinary Tract Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Physicians' Services Incorporated Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test whether administering one dose of an antibiotic
      before a routine shock wave lithotripsy procedure is more effective at avoiding any urinary
      infections compared to not taking an antibiotic. This is an important topic to study because
      urinary tract infections are one of the most common complications after this procedure and
      there is no clear standard of care regarding the use of pre-procedure antibiotics. Our study
      results will benefit future patients either by decreasing the rate of infections or
      decreasing the use of unnecessary antibiotics.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to the low recruitment rate and the large number lost to follow-up
  </why_stopped>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of antibiotic prophylaxis on the rate of urinary tract infection</measure>
    <time_frame>Post SWL Day 7</time_frame>
    <description>Our primary outcome will be a composite endpoint comprised of: Positive post-SWL urine culture (≥ 105 colony forming units / millilitre (CFU/ml), symptoms of cystitis (defined as new onset burning sensation or pain with voiding, frequency, urgency), or pyelonephritis or urosepsis (hospital admission with fever ≥38.5 C).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bacteriuria post-SWL (≥105 cfu/ml)</measure>
    <time_frame>7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of cystitis (new onset burning sensation or pain with voiding, frequency, urgency)</measure>
    <time_frame>7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pyelonephritis or urosepsis (hospital admission with fever ≥38.5C)</measure>
    <time_frame>7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary Symptom Score(reported as positive or negative integer)</measure>
    <time_frame>7 - 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Urolithiasis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciprofloxacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>Once, 400 mg IV</description>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <other_name>Ciprofloxacin Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5% Dextrose in water</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for SWL at St. Joseph's Hospital;

          -  18 years of age or older;

          -  Willing and able to complete Questionnaires;

          -  Willing to submit urine sample for analysis at Day 7;

          -  Able to read and speak English.

        Exclusion Criteria:

          -  Pre-SWL urine analysis positive for nitrites or urine culture reveals &gt;105 CFU/ml of
             bacteria (positive urine culture);

          -  Taking antibiotics for UTI or other cause;

          -  Requires an antibiotic post SWL;

          -  Suspected struvite stone (based on previous stone analysis, or partial staghorn);

          -  Presence of nephrostomy tube;

          -  Requiring cystoscopy on the day of SWL;

          -  Requiring ureteral stent on the day of SWL;

          -  Presence of indwelling urinary catheter or on regular clean intermittent
             catheterization (CIC);

          -  Presence of urinary diversion (ie: ileal conduit);

          -  Any history of urosepsis;

          -  Known allergic reaction to ciprofloxacin/quinolones;

          -  Patient known to be pregnant;

          -  Previous randomization in this trial;

          -  In the opinion of the urologist, it is not in the patient's best interest to
             participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hassan Razvi, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western University &amp; Lawson Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Hospital, St. Joseph's Health Care London</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2013</study_first_submitted>
  <study_first_submitted_qc>June 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2013</study_first_posted>
  <last_update_submitted>February 4, 2016</last_update_submitted>
  <last_update_submitted_qc>February 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Hassan Razvi</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Antibiotics</keyword>
  <keyword>Shock Wave Lithotripsy</keyword>
  <keyword>Urinary Tract Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

